Published: Aug, 2018
The global bioengineered protein drugs market is highly competitive due to presence of numerous and strong players, observes Transparency Market Research (TMR). Some of the key players operating in the global bioengineered protein drugs market are Abbott Laboratories, Amgen, Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Biocon Ltd., Sanofi, Eli Lilly and Company, GlaxoSmithKline plc, Panacea Biotec, Novartis AG, Johnson & Johnson, and ProBioGen AG. Leading players are adopting the key strategies such as mergers, acquisitions, and partnerships which improved their product portfolio and helped them to expand their reach. Additionally, global players are increasingly investing their money on research and development (R&D) activities for introduction of new products.
TMR anticipated the global revenue of the bioengineered protein drugs market to expand with a CAGR of 7.4% over the forecast period from 2017 to 2024 to attain value of a US$336.9 bn by the end of 2025 rising from the value of US$177.7 bn in 2016. On the basis of type of product, the therapeutic protein segment is expected to hold larger share owing to extensive activities to improve product in therapeutic protein engineering and recombinant DNA technology products. Regionally, North America is expected to account for the larger share owing to patent expiration of numerous well-known drugs in the market.
Rising Prevalence of Diseases to Boost Adoption of Bioengineered Protein Drugs
Proteins have important role in maintaining both structural and functional features of individual organisms. The long chain of amino acids are known as protein molecules that regulates the biological functions such as metabolic reactions and DNA replication of body. The bioengineered protein drugs are the fundamental factor for the conducting the biological process and come up with the efficient therapeutic agents. The bioengineered protein drug includes wide-ranging products such as hormones, vaccines, cytokines, and monoclonal antibodies. Rising prevalence of diseases including cancer, heart diseases, diabetes, and asthma is boosting demand for treatments which is boosting adoption of the bioengineered protein drugs. The aforementioned factors are driving growth of the global bioengineered protein drugs market.
The special drugs are increasingly adopted by pharmaceutical industries owing to specificity, bio-reactivity, safety, and success rate in treating chronic diseases and disorders. Rising numerous chronic diseases are fuelling demand for novel therapeutics which in turn is boosting adoption of bioengineered protein drugs. This is key factor driving growth of the global bioengineered protein drugs market.
High Cost of Manufacturing to Hamper Growth
However, high cost of the manufacturing bioengineered protein drugs are limiting growth of the bioengineered protein drugs market. Complications in treatment of numerous diseases with the drugs of bioengineered protein drugs hinder growth of bioengineered protein drugs market globally. Nevertheless, technological advancement in manufacturing of bioengineering drug proteins aimed at the specific drug delivery methods for maintaining its efficiency and rising expenditure on healthcare are the creating lucrative opportunities for growth of the global bioengineered protein drugs market.
This information is comprised in the new report by TMR, titled “Bioengineered Protein Drugs Market (Drug Type - Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis), Therapeutic Proteins (Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytics), and Vaccines; Disease Condition - Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, and Neurodegenerative; End User - Pharmaceutical and Biotechnology Companies, CROs, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.”
The global bioengineered protein drugs market has been segmented as presented:
By Drug Type:
- Monoclonal Antibodies
- Therapeutic Proteins
- Blood Factor
- Enzyme Therapy
By Disease Condition:
- Autoimmune Disorder
- Infectious Disease
By End User:
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453